Cyanvac LLC’s mission is to tackle the world’s most pressing infectious diseases with vaccines that can be easily delivered worldwide. We are a technology-driven company with a proprietary parainfluenza virus 5 (PIV5)-based vaccine platform. This platform enables us to make robust, intranasal vaccines that are easy to administer, easy to transport, and easy to manufacture. In preclinical studies we have shown our vaccines produce robust cellular, humoral, and mucosal immunity. Our pipeline features two clinical stage vaccines and several vaccines in preclinical development.